Cagrilintide dosage protocol

What the compound is

Cagrilintide is a long-acting analogue of natural amylin, a pancreatic hormone that helps induce satiety (the feeling of fullness) (PMID 34798060, PMID 40865172). It is being investigated for weight management (PMID 34798060). Cagrilintide is often studied in combination with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, with this combination referred to as CagriSema (PMID 40544433, PMID 38286487, PMID 40022548, PMID 40544432, PMID 37364590, PMID 40865172).

How it is thought to work

Cagrilintide, as an amylin analogue, is understood to induce satiety, which is relevant for weight management (PMID 34798060). When co-administered with semaglutide (a GLP-1 receptor agonist), the combination aims to increase weight loss and potentially improve cardiometabolic variables, leveraging the synergistic effects of these hormones (PMID 40022548, PMID 40865172).

Human evidence so far

In a phase 2 human trial of adults with type 2 diabetes, once-weekly cagrilintide (2.4 mg) alone led to a mean body weight reduction of -8.1% from baseline to week 32 (PMID 37364590). A separate phase 2 human dose-finding trial in adults without diabetes showed varying body weight reductions with different cagrilintide doses, up to 4.5 mg (PMID 34798060).

Multiple human phase 3a trials have investigated cagrilintide when combined with semaglutide (CagriSema). In adults without diabetes who had overweight or obesity, CagriSema (2.4 mg each) resulted in a mean body weight reduction of -20.4% from baseline to week 68, compared to -3.0% with placebo (PMID 40544433). In adults with type 2 diabetes and obesity, CagriSema (2.4 mg each) led to a mean body weight reduction of -13.7% from baseline to week 68, versus -3.4% with placebo (PMID 40544432). In this same population, CagriSema also resulted in more patients achieving a glycated hemoglobin level of 6.5% or less compared to placebo (73.5% vs 15.9%) (PMID 40544432).

A network meta-analysis of GLP-1 receptor agonists, which included CagriSema, indicated that CagriSema resulted in the highest weight loss (mean difference -14.03 kg) in patients with type 2 diabetes compared to placebo (PMID 38286487). Another systematic review and network meta-analysis showed CagriSema achieved substantial weight loss at one year (-14.8%) when compared with lifestyle modification alone in adults with overweight or obesity (PMID 42419792).

The primary adverse events reported in human trials for CagriSema were gastrointestinal, including nausea and vomiting (PMID 40544433, PMID 40544432). Fatigue risk was also increased with CagriSema (PMID 42419792).

Open questions and limitations

While CagriSema has shown significant weight loss benefits in humans, concerns about safety, particularly gastrointestinal adverse events, are noted, especially with higher doses (PMID 38286487, PMID 40022548). Sustaining the weight loss achieved with GLP-1-based therapies, including combinations like CagriSema, remains an outstanding question, potentially requiring lifelong pharmacological treatment (PMID 40022548, PMID 40865172).

Key terms explained

**Amylin analogue:** A synthetic compound that mimics the action of natural amylin, a hormone produced by the pancreas that helps regulate blood sugar and promotes satiety (PMID 34798060).

**Glucagon-like peptide-1 (GLP-1) receptor agonist:** A type of medication that mimics the effects of GLP-1, a hormone involved in blood sugar regulation, appetite, and digestion (PMID 38286487, PMID 40022548).

**Satiety:** The state of feeling full or satisfied after eating, which helps to control food intake (PMID 34798060).

**Glycated hemoglobin (HbA1c):** A measure that reflects average blood sugar levels over the past two to three months, used to monitor diabetes control (PMID 37364590, PMID 40544432).